Kent E. Kester

8.1k total citations · 2 hit papers
54 papers, 4.7k citations indexed

About

Kent E. Kester is a scholar working on Public Health, Environmental and Occupational Health, Molecular Biology and Immunology. According to data from OpenAlex, Kent E. Kester has authored 54 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Public Health, Environmental and Occupational Health, 22 papers in Molecular Biology and 16 papers in Immunology. Recurrent topics in Kent E. Kester's work include Malaria Research and Control (32 papers), Mosquito-borne diseases and control (21 papers) and vaccines and immunoinformatics approaches (19 papers). Kent E. Kester is often cited by papers focused on Malaria Research and Control (32 papers), Mosquito-borne diseases and control (21 papers) and vaccines and immunoinformatics approaches (19 papers). Kent E. Kester collaborates with scholars based in United States, United Kingdom and Belgium. Kent E. Kester's co-authors include D. Gray Heppner, Joe Cohen, Urszula Krzych, W. Ripley Ballou, Christian F. Ockenhouse, Gérald Voss, Nadia Tornieporth, José A. Stoute, W. Ripley Ballou and Danilo R. Casimiro and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Kent E. Kester

54 papers receiving 4.6k citations

Hit Papers

A Preliminary Evaluation of a Recombinant Circumsporozoit... 1997 2026 2006 2016 1997 2020 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalaria
    1997 652 citations José A. Stoute, M. Slaoui et al. New England Journal of Medicine profile →
  2. The promise of mRNA vaccines: a biotech and industrial perspective
    2020 325 citations Kent E. Kester et al. profile →

Peers

Kent E. Kester
Joe Cohen United States
Christian F. Ockenhouse United States
D. Gray Heppner United States
Martha Sedegah United States
W. Ripley Ballou United States
David E. Lanar United States
Michael Theisen Denmark
W. Ripley Ballou United States
David L. Narum United States
Walter R. Weiss United States
Joe Cohen United States
Kent E. Kester
Citations per year, relative to Kent E. Kester Kent E. Kester (= 1×) peers Joe Cohen

Countries citing papers authored by Kent E. Kester

Since Specialization
Citations

This map shows the geographic impact of Kent E. Kester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kent E. Kester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kent E. Kester more than expected).

Fields of papers citing papers by Kent E. Kester

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kent E. Kester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kent E. Kester. The network helps show where Kent E. Kester may publish in the future.

Co-authorship network of co-authors of Kent E. Kester

This figure shows the co-authorship network connecting the top 25 collaborators of Kent E. Kester. A scholar is included among the top collaborators of Kent E. Kester based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kent E. Kester. Kent E. Kester is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weiner, January, David Lewis, Jeroen Maertzdorf, et al.. (2019). Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium. Scientific Reports. 9(1). 20362–20362. 24 indexed citations
2.
3.
Antonic, Vlado, Alexander Stojadinovic, Kent E. Kester, et al.. (2013). Significance of Infectious Agents in Colorectal Cancer Development. Journal of Cancer. 4(3). 227–240. 59 indexed citations
4.
White, Michael, Philip Bejon, Ally Olotu, et al.. (2013). The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against Plasmodium falciparum Infection. PLoS ONE. 8(4). e61395–e61395. 122 indexed citations
5.
Lumsden, Joanne M., Robert Schwenk, Lisa Rein, et al.. (2011). Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells. PLoS ONE. 6(7). e20775–e20775. 68 indexed citations
6.
Polhemus, Mark E., Shon Remich, Bernhards Ogutu, et al.. (2009). Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area. PLoS ONE. 4(7). e6465–e6465. 94 indexed citations
7.
Shott, Joseph P., Shannon McGrath, Maria Grazia Pau, et al.. (2008). Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-γ and antibody responses in mice. Vaccine. 26(23). 2818–2823. 38 indexed citations
8.
Kester, Kent E., James F. Cummings, Christian F. Ockenhouse, et al.. (2008). Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine. 26(18). 2191–2202. 99 indexed citations
9.
10.
Stewart, V. Ann, Douglas S. Walsh, Shannon McGrath, et al.. (2006). Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. Vaccine. 24(42-43). 6493–6502. 28 indexed citations
11.
Ockenhouse, Christian F., Evelina Angov, Kent E. Kester, et al.. (2005). Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine☆. Vaccine. 24(15). 3009–3017. 73 indexed citations
12.
Bojang, Kalifa, Margaret Pinder, Opokua Ofori‐Anyinam, et al.. (2005). Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine. 23(32). 4148–4157. 64 indexed citations
13.
Pichyangkul, Sathit, Montip Gettayacamin, Robert F. Miller, et al.. (2004). Pre-clinical evaluation of the malaria vaccine candidate . MSP1 formulated with novel adjuvants or with alum. Vaccine. 22(29-30). 3831–3840. 49 indexed citations
14.
Sun, Peifang, Robert Schwenk, Katherine White, et al.. (2003). Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ. The Journal of Immunology. 171(12). 6961–6967. 183 indexed citations
15.
Ballou, W. Ripley, Kent E. Kester, & D. Gray Heppner. (2002). Pre-Erythrocytic Malaria Vaccines to Prevent <i>Plasmodium falciparum</i> Malaria. PubMed. 80. 253–261. 4 indexed citations
16.
Kester, Kent E., Denise McKinney, Nadia Tornieporth, et al.. (2001). Efficacy of Recombinant Circumsporozoite Protein Vaccine Regimens against ExperimentalPlasmodium falciparumMalaria. The Journal of Infectious Diseases. 183(4). 640–647. 199 indexed citations
17.
Heppner, D. Gray, et al.. (2001). New World monkey efficacy trials for malaria vaccine development: critical path or detour?. Trends in Parasitology. 17(9). 419–425. 17 indexed citations
18.
Doherty, J.F., M Pinder, Nadia Tornieporth, et al.. (1999). A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.. American Journal of Tropical Medicine and Hygiene. 61(6). 865–868. 66 indexed citations
19.
Stoute, José A., M. Slaoui, D. Gray Heppner, et al.. (1997). A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalaria. New England Journal of Medicine. 336(2). 86–91. 652 indexed citations breakdown →
20.
Kester, Kent E., et al.. (1996). Granulomatous Pneumocystis carinii Pneumonia in Patients with Low-Grade Lymphoid Malignancies: A Diagnostic Dilemma. Clinical Infectious Diseases. 22(6). 1111–1112. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joe Cohen Breakdown of academic impact, for papers by Christian F. Ockenhouse Breakdown of academic impact, for papers by D. Gray Heppner Breakdown of academic impact, for papers by Martha Sedegah Breakdown of academic impact, for papers by W. Ripley Ballou Breakdown of academic impact, for papers by David E. Lanar Breakdown of academic impact, for papers by Michael Theisen Breakdown of academic impact, for papers by W. Ripley Ballou Breakdown of academic impact, for papers by David L. Narum Breakdown of academic impact, for papers by Walter R. Weiss
Rankless by CCL
2026